bonyf Advances to Phase 2 in Development of Alginate-Organic Denture Fixative Cream
- bonyf advances to Phase 2 in developing Alginate-Organic Denture Fixative Cream
- Positive outcomes in Phase 1 lead to confidence in product's potential
- Company aims to redefine denture care standards with innovative formula
bonyf NV / Key word(s): Research Update/Product Launch
|
bonyf Advances to Phase 2 in Development of Alginate-Organic Denture Fixative Cream
Ghent (Belgium), 2 April 2024, 6:00 a.m.; bonyf NV (Mnemonic: MLBON), the next-generation oral comfort expert, is a Euronext Paris listed company and specializes in the development, production and marketing of oral, denture, orthodontic and wound care products, is thrilled to announce the progression to Phase 2 in the development of its revolutionary Alginate-Organic Denture Fixative Cream. Following the successful completion of Phase 1, where promising initial results were obtained, the company is now entering a critical stage in refining and validating the product's efficacy.
Throughout Phase 1, bonyf's dedicated team of researchers and scientists conducted rigorous testing to evaluate the performance and safety of the Alginate-Organic Denture Fixative Cream. The positive outcomes achieved during this phase have propelled the project forward, instilling confidence in the potential of this groundbreaking formula.
"We are excited to enter Phase 2 of development for our Alginate-Organic Denture Fixative Cream", said Jean-Pierre Bogaert, CEO at bonyf. "The progress we have made thus far is a testament to our commitment to innovation and excellence striving for maximum comfort in oral care."
The Alginate-Organic Denture Fixative Cream represents a significant advancement in denture care, harnessing the natural benefits of Alginate and Organic ingredients to deliver superior grip and comfort for denture wearers. With Phase 2 now underway, bonyf aims to further optimize and conduct comprehensive testing to validate its efficacy and safety.